Written By: Gary Hite, Research Content Writer
Reviewed By: Natalie Kunsman, M.D., Board-Certified Physician
Last Reviewed: September 8, 2026
The C-terminal decapeptide of kisspeptin anchors much of the structure-activity relationship (SAR) work surrounding this peptide family. For research teams mapping how amino acid sequence translates into receptor activity, this fragment is one of the most informative tools on the bench. This article breaks down what defines the decapeptide, why it retains activity at the kisspeptin receptor in laboratory models, and which structural features drive that activity. Read it as a working reference for designing assays, selecting fragments, and interpreting SAR data. All information here is provided for professional researchers and academic study only.
Research use notice: Kisspeptin and its fragments are supplied and described strictly for in vitro and laboratory research purposes. These materials are not for human consumption, not for veterinary use, and not intended to diagnose, treat, cure, or prevent any condition.
The Kisspeptin Peptide Family at a Glance
Kisspeptin is encoded by the KISS1 gene, which directs synthesis of a precursor protein of roughly 145 amino acids. Endogenous processing cleaves that precursor into a set of shorter peptides that differ in length but share an identical C-terminal region. The principal family members studied in the literature are kisspeptin-54, kisspeptin-14, kisspeptin-13, and kisspeptin-10.
Start your reading with one structural fact, because it organizes everything that follows: each of these fragments terminates in the same ten-residue sequence. That shared tail is the C-terminal decapeptide, and it is the common denominator behind the activity reported across the whole family. When you compare assay data between the longer and shorter forms, you are largely comparing how the surrounding residues modulate the behavior of one conserved business end.
Defining the C-Terminal Decapeptide
The C-terminal decapeptide, often labeled kisspeptin-10, corresponds to the final ten residues of kisspeptin-54, spanning positions 45 to 54 of that longer peptide. In its human form the sequence is Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe, written YNWNSFGLRF, with a molecular formula of C63H83N17O14. The defining feature to note immediately is the C-terminal amidation: the terminal phenylalanine carries an amide group rather than a free carboxyl, giving the canonical RF-amide ending. You can cross-check the kisspeptin-10 structural data against public chemical databases before you design around it.
That amidated arginine-phenylalanine motif places kisspeptin within the broader RFamide peptide family, a group of signaling peptides unified by this structural signature. When you source a research fragment, confirm on the certificate of analysis that the preparation is the amidated form, because the amide is not a cosmetic detail. It is a determinant of activity, as the SAR data below make clear.
Why the Decapeptide Retains Activity
The headline result from decades of fragment studies is straightforward. The C-terminal decapeptide is the shortest fragment that preserves full activity at the kisspeptin receptor in cell-based research models. Truncating the longer forms down to ten residues does not abolish receptor engagement, which tells you that the information needed to recognize and activate the receptor is concentrated in this short tail. Reported activity data go further, indicating that the shorter fragments can match or even exceed the potency of the 54-residue form.
Use this as a design principle. If your project needs a compact, well-characterized agonist tool, kisspeptin-10 research material gives you the minimal functional unit without the synthetic and stability burdens that come with the full-length form. If your project instead targets the contributions of upstream residues, the decapeptide becomes your baseline reference point against which longer constructs are measured.
Structure-Activity Relationship: The Critical Residues
SAR research dissects the decapeptide residue by residue, substituting, deleting, or chemically modifying positions and reading the consequences in functional assays. These patterns are catalogued alongside the receptor’s broader kisspeptin receptor pharmacology in established reference databases, which you can use to cross-check agonist and antagonist profiles. A few clear patterns emerge.
The C-Terminal Amide
The amidated C-terminus is essential. Removing the amide, converting the terminus to a free acid, or deleting the terminal residue produces a steep loss of potency in reported assays. Treat the C-terminal amide as a non-negotiable feature when interpreting why one preparation performs and another does not.
The Terminal Aromatic Residue and the Penultimate Arginine
The terminal phenylalanine and the adjacent arginine sit at the heart of receptor recognition. Substitutions at these positions are among the most disruptive in the SAR record, which marks them as primary contact residues. The aromatic ring at the C-terminus and the positive charge of the arginine appear to cooperate in anchoring the peptide to its binding site.
The Tryptophan and the Core
Moving inward, the tryptophan residue and the central segment of the decapeptide contribute to potency as well, though the tolerance for change varies position by position. Some substitutions in the core are accommodated with modest effect, while others reduce activity, giving medicinal chemistry teams a map of where the sequence is flexible and where it is constrained. This map is exactly what you exploit when you set out to engineer analogs.
Receptor Engagement in Cell-Based Assays
The kisspeptin receptor, KISS1R (also referred to as GPR54), is a G protein-coupled receptor that signals through the Gq/11 pathway in research systems. Activation stimulates phospholipase C, generating second messengers that mobilize intracellular calcium and engage protein kinase C. In practice, that signaling cascade is what your SAR readouts are measuring.
This matters for assay design. Functional endpoints such as intracellular calcium flux and inositol phosphate accumulation are the standard reporters used to rank fragment and analog potency. These readouts are typically run in cell culture models, where receptor-expressing lines report activation in real time. When you compare the decapeptide against modified sequences, choose a readout that reflects this pathway so your potency rankings map cleanly onto receptor activation rather than onto a downstream artifact.
Metabolic Stability and Analog Design
The native decapeptide is potent but not durable. In research preparations it is susceptible to enzymatic degradation, which limits its functional half-life and complicates experiments that require sustained receptor occupancy. The literature identifies a key site of proteolytic vulnerability at the glycine-leucine bond within the sequence, with the matrix metalloproteinases MMP-2 and MMP-9 among the enzymes implicated in cleavage.
This vulnerability is also an opportunity, and it explains a large share of modern kisspeptin SAR effort. To extend stability, research teams have explored substitutions at and around the cleavage site, incorporation of non-natural amino acids, and the use of D-amino acid replacements to resist proteolysis. The goal across these strategies is consistent: preserve the C-terminal features that drive activity while reinforcing the backbone against degradation. Beyond the intrinsic resistance of the sequence itself, build in a workflow for evaluating solution stability across the life of an experiment, and prioritize analogs designed with these stability considerations rather than relying on the unmodified native fragment.
Handling and Characterization in the Laboratory
Good SAR data start with well-handled material. Follow established lyophilized peptide storage practice by keeping the material cold and protected from light and moisture. When you prepare working stock, treat reconstitution solvent selection as a deliberate decision rather than an afterthought, since the solvent shapes solubility and downstream assay behavior. Aliquot reconstituted stock to avoid repeated freeze-thaw cycles, which can degrade peptide integrity and introduce variability between runs.
Verify before you assay. Confirm identity and purity by HPLC and mass spectrometry, and review the certificate of analysis for the specific lot in hand, paying particular attention to confirmation of the amidated C-terminus and to net peptide content. Building these checks into your workflow keeps your structure-activity conclusions tied to the molecule you intend to study rather than to a degradation product or an impurity.
Conclusion
The C-terminal decapeptide gives your laboratory a precise, well-mapped entry point into kisspeptin structure-activity research. Anchor your work on three load-bearing features: the C-terminal amide, the terminal aromatic residue, and the penultimate arginine, and treat the core sequence as the tunable region where analog design earns its gains. Read potency through the Gq/11 signaling pathway with calcium or inositol phosphate endpoints, design around the proteolytic weak point, and gate every experiment behind rigorous identity and purity verification.
Document each lot, confirm the amidated C-terminus, and verify net peptide content before you assay, because clean handling is what keeps your conclusions tied to the molecule you intended to study. When you are ready to source well-characterized research peptides for structure-activity work, start with material backed by transparent analytical documentation. Approach the decapeptide as a model system, and it will reward methodical, compliance-minded investigation.
FAQs
What is the C-terminal decapeptide of kisspeptin?
It is the ten-residue C-terminal fragment shared by every member of the kisspeptin family, commonly designated kisspeptin-10 and corresponding to positions 45 to 54 of kisspeptin-54. In its human form the sequence is Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe with an amidated C-terminus. Treat it as the conserved active core that drives receptor recognition across the family.
Why is the C-terminal amide important for activity?
The amidated C-terminus is essential for receptor activation in research models. Removing the amide, converting it to a free acid, or deleting the terminal residue produces a steep loss of potency. When you evaluate a preparation, confirm the amidated form first, because the amide is a determinant of activity rather than a cosmetic detail.
Which residues in kisspeptin-10 are most critical?
Focus on the terminal phenylalanine and the adjacent arginine, the RF-amide pair that anchors the peptide to its binding site, since substitutions there are the most disruptive. The tryptophan and the central segment also contribute, with tolerance varying position by position. Use this map to decide where the sequence is flexible and where it is constrained before designing analogs.
How should kisspeptin-10 be stored and reconstituted for research?
Store the lyophilized peptide cold and protected from light and moisture, then reconstitute it in an appropriate sterile solvent for your in vitro protocol. Aliquot reconstituted stock to avoid repeated freeze-thaw cycles, which degrade integrity and add run-to-run variability. Treat solvent choice as a deliberate decision, because it shapes solubility and downstream assay behavior.
How can researchers verify the identity and purity of kisspeptin-10?
Confirm identity and purity by HPLC and mass spectrometry, and review the certificate of analysis for the specific lot in hand. Pay particular attention to confirmation of the amidated C-terminus and to net peptide content. Building these checks into your workflow keeps your structure-activity conclusions tied to the molecule you intend to study.
Compliance and Disclaimer: This article is intended solely for educational and informational use by qualified researchers, scientists, and academic professionals. Kisspeptin and all related fragments described here are research chemicals supplied strictly for in vitro laboratory and scientific research use only.
These products are not for human consumption and not for animal consumption. They are not drugs, foods, dietary supplements, or cosmetics. Nothing in this article should be interpreted as a medical claim, a therapeutic recommendation, or a suggestion of any use in humans or animals. No statement here has been evaluated by any regulatory authority, and none of these materials is intended to diagnose, treat, cure, or prevent any disease or condition.
By accessing this content, the reader confirms that they are a qualified professional acquiring and handling these materials in a controlled research setting, in compliance with all applicable laws, regulations, and institutional guidelines. Any handling, storage, and disposal must follow established laboratory safety practices.